Drug Profile

G 305

Alternative Names: Cancer vaccine NY-ESO-1 - Immune Design; G-305; ID-G305; IDC-G305; NY-ESO-1/GLA-SE cancer vaccine - Immune Design

Latest Information Update: 30 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Immune Design
Class Cancer vaccines; Peptide vaccines; Peptides
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Soft tissue sarcoma
New Molecular Entity No

Highest Development Phases

Discontinued Breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Sarcoma

Most Recent Events

10 Mar 2016 G 305 receives Orphan Drug status for Soft tissue sarcoma in European Union
08 Jan 2016 G 305 receives Orphan Drug status for Soft tissue sarcoma in USA
13 May 2015 Interim efficacy and adverse events data from a phase I trial in Cancer released by Immune Design

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com